Engineered cyclic peptide targeting ITGA5 disrupts tumor–stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma. This evidence concerns the gene ITGA5 and pancreatic ductal adenocarcinoma.